Arkenau et al. “A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.” Annals of Oncology 2011. DOI: 10.1093/annonc/mdr451.

Arkenau et al. “A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.” Annals of Oncology 2011. DOI: 10.1093/annonc/mdr451.